WallStreetZenWallStreetZen

NASDAQ: COCP
Cocrystal Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for COCP

Based on 1 analyst offering 12 month price targets for Cocrystal Pharma Inc.
Min Forecast
$10.00+557.89%
Avg Forecast
$10.00+557.89%
Max Forecast
$10.00+557.89%

Should I buy or sell COCP stock?

Based on 1 analyst offering ratings for Cocrystal Pharma Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their COCP stock forecasts and price targets.

COCP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-04

1 of 1

Forecast return on equity

Is COCP forecast to generate an efficient return?
Company
N/A
Industry
-49.01%
Market
28.28%

Forecast return on assets

Is COCP forecast to generate an efficient return on assets?
Company
N/A
Industry
28.47%

COCP revenue forecast

What is COCP's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$7.5M
Avg 2 year Forecast
$2.0M

COCP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
COCP$1.52$10.00+557.89%Buy
NRBO$3.12N/AN/A
EVAX$4.19$11.00+162.53%Strong Buy
IMRN$2.60N/AN/A
CDIO$0.75$1.35+80.24%Buy
View Top Biotech Stocks

Cocrystal Pharma Stock Forecast FAQ

Is Cocrystal Pharma Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: COCP) stock is to Buy COCP stock.

Out of 1 analyst, 0 (0%) are recommending COCP as a Strong Buy, 1 (100%) are recommending COCP as a Buy, 0 (0%) are recommending COCP as a Hold, 0 (0%) are recommending COCP as a Sell, and 0 (0%) are recommending COCP as a Strong Sell.

If you're new to stock investing, here's how to buy Cocrystal Pharma stock.

What is COCP's revenue growth forecast for 2024-2025?

(NASDAQ: COCP) Cocrystal Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 247.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.29%.

Cocrystal Pharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast COCP's revenue for 2024 to be $76,303,425, with the lowest COCP revenue forecast at $76,303,425, and the highest COCP revenue forecast at $76,303,425.

In 2025, COCP is forecast to generate $20,347,580 in revenue, with the lowest revenue forecast at $20,347,580 and the highest revenue forecast at $20,347,580.

What is COCP's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: COCP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 28.47%.

What is COCP's Price Target?

According to 1 Wall Street analyst that have issued a 1 year COCP price target, the average COCP price target is $10.00, with the highest COCP stock price forecast at $10.00 and the lowest COCP stock price forecast at $10.00.

The Wall Street analyst predicted that Cocrystal Pharma's share price could reach $10.00 by Apr 4, 2025. The average Cocrystal Pharma stock price prediction forecasts a potential upside of 557.89% from the current COCP share price of $1.52.

What is COCP's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: COCP) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.